<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00802243</url>
  </required_header>
  <id_info>
    <org_study_id>2007-003545-32</org_study_id>
    <nct_id>NCT00802243</nct_id>
  </id_info>
  <brief_title>Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid</brief_title>
  <acronym>ARABUL</acronym>
  <official_title>Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid. An Open Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bullous pemphigoid (BP) is the most common blistering auto-immune disease of skin with an
      incidence estimated to 400 new cases per year. Topical corticosteroid therapy is considered
      the standard treatment for bullous pemphigoïd in 2002. Topical corticosteroid requires an
      initial large hospitalization during the acute phase and rehospitalization during relapse.
      The usefulness of immunosuppressive drugs have suggested by uncontrolled study.

      In this way, leflunomide could be an alternative therapy, and to reduce relapse and/or
      resistance risks.

      This study could prove the efficacity of leflunomide, associated with short time topical
      corticosteroids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pre-inclusion stage: Case history, clinical examination, laboratory study, inclusion criteria
      checking.

      Inclusion stage: Inclusion and exclusion criteria checking, clinical examination, disease
      follow-up, written inform consent.

      Ambulatory hospitalisation, laboratory study.

      Treatment and follow-up of the patients.

      Clobetasol propionate cream application and leflunomide introduction.

      After inclusion, the treatment will begin with 40 g topical corticosteroid per day and 20 mg
      leflunomide per day.

      Topical corticosteroids will be progressively decreased during 5 months and stopped.

      Follow-up: monthly during one year in the department of dermatology, university hospital
      (clinical examination, laboratory study).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2007</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stage 1 : complete clinical remission after 6 months treatment for 9 patients at least among 15 appraisable patients.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 2 : complete clinical remission after 6 months treatment for 27 patients at least among 43 appraisable patients.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the rate of clinical complete remission at M9 and M12.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the number of patients with immunological remission at M6, M9 and M12.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate monthly the tolerance of leflunomide.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Bullous Pemphigoid</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leflunomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult ≥ 65 years old

          -  Bullous pemphigoid :

               -  Newly diagnosed bullous pemphigoid : No treatment or topical corticosteroids
                  therapy for less than one month

               -  BP diagnosed : Resistance of the BP to the treatment or recurrence 6 months at
                  least after diagnosis

          -  Follow up monthly during one year accepted

          -  Written Inform Consent

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe BEDANE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Limoges</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christophe BEDANE, MD</last_name>
    <phone>0555056430</phone>
    <email>christophe.bedane@chu-limoges.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Limoges University Hospital</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe BEDANE, MD</last_name>
      <phone>0555056430</phone>
      <email>christophe.bedane@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Agnès SPARSA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Marie BONNETBLANC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie CENDRAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bordeaux University Hospital</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie Sylvie DOUTRE, MD</last_name>
      <phone>0557656432</phone>
    </contact>
    <investigator>
      <last_name>Marie Sylvie DOUTRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toulouse University Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carle PAUL, MD</last_name>
      <phone>0561777675</phone>
    </contact>
    <investigator>
      <last_name>Carle PAUL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2008</study_first_submitted>
  <study_first_submitted_qc>December 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2008</study_first_posted>
  <last_update_submitted>December 3, 2008</last_update_submitted>
  <last_update_submitted_qc>December 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2008</last_update_posted>
  <keyword>Bullous pemphigoid</keyword>
  <keyword>leflunomide</keyword>
  <keyword>corticosteroid treatment reduction</keyword>
  <keyword>Patients are screened by: the physicians in different departments of the hospital, the liberal dermatologists and the general practicioners.</keyword>
  <keyword>Phase I: Patients will be referred to the investigators of Dupuytren Hospital Dermatology Department.</keyword>
  <keyword>Phase II: Patients will be referred to the investigators of Purpan (Toulouse), Haut Leveque (Pessac) and Dupuytren (Limoges) Hospitals.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemphigoid, Bullous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leflunomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

